Kamada

Kamada Revenue

The The revenue of Kamada (KMDA) as of Nov 2, 2026 is 180.46 M USD. In the previous year, The revenue was 160.95 M USD — a change of 12.12% (higher).

Revenue

180.46 MUSD

YoY

12.12%

Last updated:

In 2025, Kamada's sales reached 180.46 M USD, a 12.12% difference from the 160.95 M USD sales recorded in the previous year.

Revenue has compounded at 14.8% per year over the past 19 years to 180.46 M USD.

The Kamada Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
Date
Revenue
Jan 1, 2023
142.52 M USD
Jan 1, 2024
160.95 M USD
Jan 1, 2025
180.46 M USD
Jan 1, 2026 (e)
202.96 M USD
Jan 1, 2027 (e)
228.16 M USD
Jan 1, 2028 (e)
248.25 M USD
Jan 1, 2029 (e)
266.22 M USD
Jan 1, 2030 (e)
282.73 M USD
The Kamada Revenue history
YEARRevenueYoY
est282.73 MUSD+6.20%
est266.22 MUSD+7.24%
est248.25 MUSD+8.80%
est228.16 MUSD+12.42%
est202.96 MUSD+12.47%
180.46 MUSD+12.12%
160.95 MUSD+12.93%
142.52 MUSD+10.19%
129.34 MUSD+24.79%
103.64 MUSD-22.22%
133.25 MUSD+4.76%
127.19 MUSD+11.11%
114.47 MUSD+11.32%
102.83 MUSD+32.69%
77.49 MUSD+10.53%
70.11 MUSD-2.52%
71.93 MUSD+1.84%
70.62 MUSD-2.82%
72.68 MUSD+29.96%
55.92 MUSD+54.16%
36.27 MUSD+142.16%
14.98 MUSD-1.54%
15.21 MUSD+13.22%
13.44 MUSD+2.57%
13.10 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Kamada Revenue

Kamada Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
142.52 M USD
9.73 M USD
8.28 M USD
Jan 1, 2024
160.95 M USD
20.05 M USD
14.46 M USD
Jan 1, 2025
180.46 M USD
26.23 M USD
20.20 M USD
Jan 1, 2026 (e)
202.96 M USD
35.66 M USD
27.54 M USD
Jan 1, 2027 (e)
228.16 M USD
42.96 M USD
33.26 M USD
Jan 1, 2028 (e)
248.25 M USD
47.98 M USD
37.30 M USD
Jan 1, 2029 (e)
266.22 M USD
57.44 M USD
44.13 M USD
Jan 1, 2030 (e)
282.73 M USD
70.73 M USD
54.51 M USD

Kamada Margins

Kamada stock margins

The Kamada margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Kamada. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Kamada.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
38.94 %
6.83 %
5.81 %
Jan 1, 2024
43.47 %
12.46 %
8.99 %
Jan 1, 2025
42.34 %
14.54 %
11.19 %
Jan 1, 2026 (e)
42.34 %
17.57 %
13.57 %
Jan 1, 2027 (e)
42.34 %
18.83 %
14.58 %
Jan 1, 2028 (e)
42.34 %
19.33 %
15.03 %
Jan 1, 2029 (e)
42.34 %
21.58 %
16.57 %
Jan 1, 2030 (e)
42.34 %
25.02 %
19.28 %

Kamada Stock analysis

What does Kamada do? Kamada Ltd is an Israel-based company specializing in the development and marketing of biopharmaceutical products for humans and animals. The company was founded in 1990 by a team of experienced executives and scientists from the biotech industry. Since its inception, Kamada has become a global leader in plasma fractionation and the production of antibodies and enzymes. The company is listed on the NASDAQ and the Tel Aviv Stock Exchange and has over 450 employees in its facilities in Israel and the USA. Kamada's business model is based on combining innovative science and technology to develop products and therapies for rare and severe diseases. The company is constantly working to improve its production processes to deliver more efficient and cost-effective products. Kamada operates in three divisions: human therapeutics, veterinary medicine, and plasma research. The human therapeutics division develops and markets products for the treatment of diseases such as alpha-1 antitrypsin deficiency, immunoglobulin deficiency, hemophilia, and other serious conditions. The veterinary medicine division offers products for the treatment of diseases in dogs, horses, and cows to veterinary professionals. The plasma research division focuses on developing technologies for the production of plasma derivatives and discovering new applications for plasma proteins. Kamada has a wide range of products on the market, including its flagship product Glassia, which is used to treat alpha-1 antitrypsin deficiency, a rare genetic disease that can affect the lungs. The company also produces intravenous immunoglobulin preparations for the treatment of immune deficiencies and other immune system disorders, as well as recombinant factor VIII for the treatment of hemophilia. In veterinary medicine, Kamada offers products such as Equine Seramune, designed for horses and used to treat life-threatening infections caused by bacteria found in the intestines of horses. The company also produces products for the treatment of mastitis, an infection of the milk ducts in cows, and gastrointestinal tract infections in dogs. Kamada takes pride in playing a leading role in plasma research and technology. The company's research has resulted in groundbreaking technologies that allow for the faster and more cost-effective production of important plasma proteins than was previously possible. Kamada works closely with other research institutions and companies to collaborate on solutions for severe and rare diseases. Over the years, Kamada has received numerous awards and recognition for its groundbreaking research and development work. The company is committed to continuing to develop innovative products and therapies to improve the lives of patients with rare and severe diseases. Overall, Kamada Ltd has experienced remarkable growth in recent years. It is a company that plays a leading role in the market for biopharmaceutical products based on top-notch scientific research and efficient technology. In the future, Kamada will undoubtedly continue to develop groundbreaking products and therapies to improve the lives of patients worldwide. Kamada is one of the most popular companies on Eulerpool.

Revenue Details

Understanding Kamada's Sales Figures

The sales figures of Kamada originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Kamada’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Kamada's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Kamada’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Kamada stock

The revenue of Kamada is 180.46 M USD in 2025.

The revenue of Kamada changed from 160.95 M USD to 180.46 M USD, representing a 12.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The revenue Kamada since 2006 – with annual values, charts, and detailed analysis.

Revenue is the total value of all goods sold in a period. It is calculated by multiplying the quantity of each product sold by its selling price. Revenue does not include any costs (material costs, personnel costs, etc.), whereas net proceeds only deduct revenue reductions associated with the sale (discounts, etc.).

The revenue's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The revenue's Kamada historically and in real time.

The revenue in assessing a stock

Revenue is an important financial measure used in the valuation of stocks. It is a measure of a company's economic activity and can serve as an indicator of the company's success. Revenue is considered one of the most important factors in stock valuation. In addition, revenue can also be used to calculate other financial measures such as earnings per share and price-earnings ratio.

History and utilization of revenue

Revenue has long been considered one of the most important financial indicators. It was used in the 19th century as one of the first financial indicators to measure a company's economic activity. Since then, revenue has been regularly used to evaluate companies.

Revenue is usually calculated as a percentage of the company's equity. It can also be used to determine the overall profitability of a company. There are many different types of revenue that can be used to measure a company's economic activity, such as gross revenue, net revenue, and revenue from international business.

The revenue can also be used to evaluate stocks. For example, the revenue of a company can be used to evaluate the success of the company. If a company has high revenue, it means that it is a profitable company because it has high demand for its products or services.

Calculation and Application of Revenue

In order to calculate a company's revenue, the company's income must be deducted from its expenses. The income can come from various sources, such as sales, licensing fees, services, etc. The expenses can include costs for production, procurement, inventory, sales, and administration.

The revenue can then be used to calculate various financial ratios. For example, the revenue can be used to calculate the price-earnings ratio (P/E ratio) of a company. This is a measure of a company's profitability, calculated by taking the ratio of the stock price to earnings per share.

Revenue can also be used to calculate earnings per share (EPS) of a company. This is a measure of a company's profit per share. EPS is calculated by dividing earnings by the number of shares issued.

Use of revenue by investors

Investors use revenue to evaluate stocks, as revenue is an indicator of a company's success. For example, an investor can compare a company's revenue to see how successful it is. An investor can also use a company's revenue to calculate its price-to-earnings ratio and earnings per share.

An example: An investor looks at a company that has a revenue of 25 million euros. He compares this revenue to that of the competitor, which has a revenue of 35 million euros. The investor can then see that the company with 25 million euros in revenue is less successful than the company with 35 million euros in revenue.

Advantages and Disadvantages of Revenue.

Revenue is a very useful tool for valuing stocks as it measures a company's economic activity. Revenue can also be used to calculate other financial ratios such as the price-earnings ratio and earnings per share.

However, one disadvantage is that revenue alone is not a meaningful indicator of a company's success. It is important to consider revenue in comparison to other financial metrics such as earnings per share and price-to-earnings ratio to get a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Kamada

All Key Metrics — Kamada